Abstract
Growth factors or humoral agents can support haemopoiesis in various bone marrow disorders. They have the ability to act on multiple cell lineages and in myeloid cells, and the potential to act on the neoplastic equivalent of normal cells. Anaemia is a common feature of multiple myeloma seen in at least two-thirds of patients at presentation. Erythropoietin is increasingly being used with variable effect for the treatment of this anaemia, especially in cases associated with renal failure and in patients in whom blood transfusion may be undesirable or contraindicated. We describe a patient treated with recombinant erythropoietin who developed fulminating malignant transformation. The demonstration of erythropoietin receptors on a human myeloma cell line and the occurrence of the rare complication of plasma cell leukaemia in our patient stresses the need for caution and invites detailed clinical and laboratory studies before its general use.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aoki I., Nishijima K., Homori M., Nakahara K., Higashi K., Ishikawa K. Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in multiple myeloma. Br J Haematol. 1992 Aug;81(4):463–469. doi: 10.1111/j.1365-2141.1992.tb02976.x. [DOI] [PubMed] [Google Scholar]
- Barlogie B., Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells. 1993 Mar;11(2):88–94. doi: 10.1002/stem.5530110203. [DOI] [PubMed] [Google Scholar]
- Caillette A., Barreto S., Gimenez E., Labeeuw M., Zech P. Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis? Clin Nephrol. 1993 Sep;40(3):176–178. [PubMed] [Google Scholar]
- Dessypris E., Graber S. E., Krantz S. B., Stone W. J. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood. 1988 Dec;72(6):2060–2062. [PubMed] [Google Scholar]
- Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989 Feb;73(2):517–526. [PubMed] [Google Scholar]
- Ludwig H., Fritz E., Kotzmann H., Höcker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990 Jun 14;322(24):1693–1699. doi: 10.1056/NEJM199006143222402. [DOI] [PubMed] [Google Scholar]
- MacLennan I. C., Drayson M., Dunn J. Multiple myeloma. BMJ. 1994 Apr 16;308(6935):1033–1036. doi: 10.1136/bmj.308.6935.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Okuno Y., Takahashi T., Suzuki A., Ichiba S., Nakamura K., Hitomi K., Sasaki R., Imura H. Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun. 1990 Aug 16;170(3):1128–1134. doi: 10.1016/0006-291x(90)90510-t. [DOI] [PubMed] [Google Scholar]
- Park L. S., Waldron P. E., Friend D., Sassenfeld H. M., Price V., Anderson D., Cosman D., Andrews R. G., Bernstein I. D., Urdal D. L. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood. 1989 Jul;74(1):56–65. [PubMed] [Google Scholar]
- Rogers S., Russell N. H., Morgan A. G. Effect of erythropoietin in patients with myeloma. BMJ. 1990 Sep 29;301(6753):667–667. doi: 10.1136/bmj.301.6753.667-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang X. G., Bataille R., Jourdan M., Saeland S., Banchereau J., Mannoni P., Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood. 1990 Dec 15;76(12):2599–2605. [PubMed] [Google Scholar]